Application/Control Number: 95/002,170
`Art Unit: 3991
`
`Page 45
`
`In order to ensure full consideration of any amendments, affidavits or
`
`declarations, or other documents as evidence of patentability, such documents
`
`must be submitted in response to this Office action. Submissions after the next
`
`Office action, which is intended to be an Action Closing Prosecution (ACP), will
`
`be governed by 37 CFR 1.116(b) and (d), which will be strictly enforced.
`
`All correspondence relating to this inter partes reexamination proceeding
`
`should be directed:
`
`By EFS: Registered users may submit via the electronic filing system EFS-Web
`at httQs://efs.usgto.gov/efile/my_gortal/efs-registered
`
`By Mail to: Attn: Mail Stop "Inter Partes Reexam"
`Central Reexamination Unit
`Commissioner for Patents
`P. 0. Box 1450
`Alexandria VA 22313-1450
`
`Please FAX any communications to:
`(571) 273-9900
`Central Reexamination Unit
`
`Please hand-deliver any communications to:
`Customer Service Window
`Attn: Central Reexamination Unit
`Randolph Building, Lobby Level
`401 Dulany Street
`Alexandria, VA 22314
`
`Signed:
`
`/Alan Diamond/
`Patent Reexamination Specialist
`Central Reexamination Unit 3991
`
`/Jerry D. Johnson/
`Patent Reexamination Specialist
`Central Reexamination Unit 3991
`
`Page 2832
`
`TEVA EXHIBIT 1007
`TEVA PHARMACEUTICALS USA, INC. V. MONOSOL RX, LLC
`
`

`
`Application/Control Number: 95/002,170
`Art Unit: 3991
`
`/Deborah Jones/
`
`Supervisory Patent Examiner, Art Unit 3991
`
`Page 46
`
`Page 2833
`
`TEVA EXHIBIT 1007
`TEVA PHARMACEUTICALS USA, INC. V. MONOSOL RX, LLC
`
`

`
`Index of Claims
`
`Application/Control No.
`
`95002170
`
`Examiner
`
`ALAN DIAMOND
`
`Applicant( s )/Patent Under
`Reexamination
`7897080
`
`Art Unit
`
`3991
`
`Rejected
`
`Allowed
`
`--
`
`Cancelled
`
`N
`
`Non-Elected
`
`Restricted
`
`Interference
`
`A
`
`0
`
`Appeal
`
`Objected
`
`D Claims renumbered in the same order as presented by applicant
`
`D CPA
`
`D T.D.
`
`D R.1.47
`
`CLAIM
`Final
`Original
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`26
`27
`28
`29
`30
`31
`32
`33
`34
`35
`36
`
`10/08/2012
`./
`
`DATE
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`U.S. Patent and Trademark Office
`
`Part of Paper No.: 20t2t002
`
`Page 2834
`
`TEVA EXHIBIT 1007
`TEVA PHARMACEUTICALS USA, INC. V. MONOSOL RX, LLC
`
`

`
`Index of Claims
`
`Application/Control No.
`
`95002170
`
`Examiner
`
`ALAN DIAMOND
`
`Applicant( s )/Patent Under
`Reexamination
`7897080
`
`Art Unit
`
`3991
`
`Rejected
`
`Allowed
`
`--
`
`Cancelled
`
`N
`
`Non-Elected
`
`Restricted
`
`Interference
`
`A
`
`0
`
`Appeal
`
`Objected
`
`D Claims renumbered in the same order as presented by applicant
`
`D CPA
`
`D T.D.
`
`D R.1.47
`
`CLAIM
`Final
`Original
`37
`38
`39
`40
`41
`42
`43
`44
`45
`46
`47
`48
`49
`50
`51
`52
`53
`54
`55
`56
`57
`58
`59
`60
`61
`62
`63
`64
`65
`66
`67
`68
`69
`70
`71
`72
`
`10/08/2012
`./
`
`DATE
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`U.S. Patent and Trademark Office
`
`Part of Paper No.: 20t2t002
`
`Page 2835
`
`TEVA EXHIBIT 1007
`TEVA PHARMACEUTICALS USA, INC. V. MONOSOL RX, LLC
`
`

`
`Index of Claims
`
`Application/Control No.
`
`95002170
`
`Examiner
`
`ALAN DIAMOND
`
`Applicant( s )/Patent Under
`Reexamination
`7897080
`
`Art Unit
`
`3991
`
`Rejected
`
`Allowed
`
`--
`
`Cancelled
`
`N
`
`Non-Elected
`
`Restricted
`
`Interference
`
`A
`
`0
`
`Appeal
`
`Objected
`
`D Claims renumbered in the same order as presented by applicant
`
`D CPA
`
`D T.D.
`
`D R.1.47
`
`CLAIM
`Final
`Original
`73
`74
`75
`76
`77
`78
`79
`80
`81
`82
`83
`84
`85
`86
`87
`88
`89
`90
`91
`92
`93
`94
`95
`96
`97
`98
`99
`100
`101
`102
`103
`104
`105
`106
`107
`108
`
`10/08/2012
`./
`
`DATE
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`U.S. Patent and Trademark Office
`
`Part of Paper No.: 20t2t002
`
`Page 2836
`
`TEVA EXHIBIT 1007
`TEVA PHARMACEUTICALS USA, INC. V. MONOSOL RX, LLC
`
`

`
`Index of Claims
`
`Application/Control No.
`
`95002170
`
`Examiner
`
`ALAN DIAMOND
`
`Applicant( s )/Patent Under
`Reexamination
`7897080
`
`Art Unit
`
`3991
`
`Rejected
`
`Allowed
`
`--
`
`Cancelled
`
`N
`
`Non-Elected
`
`Restricted
`
`Interference
`
`A
`
`0
`
`Appeal
`
`Objected
`
`D Claims renumbered in the same order as presented by applicant
`
`D CPA
`
`D T.D.
`
`D R.1.47
`
`CLAIM
`Final
`Original
`109
`110
`111
`112
`113
`114
`115
`116
`117
`118
`119
`120
`121
`122
`123
`124
`125
`126
`127
`128
`129
`130
`131
`132
`133
`134
`135
`136
`137
`138
`139
`140
`141
`142
`143
`144
`
`10/08/2012
`./
`
`DATE
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`U.S. Patent and Trademark Office
`
`Part of Paper No.: 20t2t002
`
`Page 2837
`
`TEVA EXHIBIT 1007
`TEVA PHARMACEUTICALS USA, INC. V. MONOSOL RX, LLC
`
`

`
`Index of Claims
`
`Application/Control No.
`
`95002170
`
`Examiner
`
`ALAN DIAMOND
`
`Applicant( s )/Patent Under
`Reexamination
`7897080
`
`Art Unit
`
`3991
`
`Rejected
`
`Allowed
`
`--
`
`Cancelled
`
`N
`
`Non-Elected
`
`Restricted
`
`Interference
`
`A
`
`0
`
`Appeal
`
`Objected
`
`D Claims renumbered in the same order as presented by applicant
`
`D CPA
`
`D T.D.
`
`D R.1.47
`
`CLAIM
`Final
`Original
`145
`146
`147
`148
`149
`150
`151
`152
`153
`154
`155
`156
`157
`158
`159
`160
`161
`162
`163
`164
`165
`166
`167
`168
`169
`170
`171
`172
`173
`174
`175
`176
`177
`178
`179
`180
`
`10/08/2012
`./
`
`DATE
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`U.S. Patent and Trademark Office
`
`Part of Paper No.: 20t2t002
`
`Page 2838
`
`TEVA EXHIBIT 1007
`TEVA PHARMACEUTICALS USA, INC. V. MONOSOL RX, LLC
`
`

`
`Index of Claims
`
`Application/Control No.
`
`95002170
`
`Examiner
`
`ALAN DIAMOND
`
`Applicant( s )/Patent Under
`Reexamination
`7897080
`
`Art Unit
`
`3991
`
`Rejected
`
`Allowed
`
`--
`
`Cancelled
`
`N
`
`Non-Elected
`
`Restricted
`
`Interference
`
`A
`
`0
`
`Appeal
`
`Objected
`
`D Claims renumbered in the same order as presented by applicant
`
`D CPA
`
`D T.D.
`
`D R.1.47
`
`CLAIM
`Final
`Original
`181
`182
`183
`184
`185
`186
`187
`188
`189
`190
`191
`192
`193
`194
`195
`196
`197
`198
`199
`200
`201
`202
`203
`204
`205
`206
`207
`208
`209
`210
`211
`212
`213
`214
`215
`216
`
`10/08/2012
`./
`
`DATE
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`U.S. Patent and Trademark Office
`
`Part of Paper No.: 20t2t002
`
`Page 2839
`
`TEVA EXHIBIT 1007
`TEVA PHARMACEUTICALS USA, INC. V. MONOSOL RX, LLC
`
`

`
`Index of Claims
`
`Application/Control No.
`
`95002170
`
`Examiner
`
`ALAN DIAMOND
`
`Applicant( s )/Patent Under
`Reexamination
`7897080
`
`Art Unit
`
`3991
`
`Rejected
`
`Allowed
`
`--
`
`Cancelled
`
`N
`
`Non-Elected
`
`Restricted
`
`Interference
`
`A
`
`0
`
`Appeal
`
`Objected
`
`D Claims renumbered in the same order as presented by applicant
`
`D CPA
`
`D T.D.
`
`D R.1.47
`
`CLAIM
`Final
`Original
`217
`218
`219
`220
`221
`222
`223
`224
`225
`226
`227
`228
`229
`230
`231
`232
`233
`234
`235
`236
`237
`238
`239
`240
`241
`242
`243
`244
`245
`246
`247
`248
`249
`250
`251
`252
`
`10/08/2012
`./
`
`DATE
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`U.S. Patent and Trademark Office
`
`Part of Paper No.: 20t2t002
`
`Page 2840
`
`TEVA EXHIBIT 1007
`TEVA PHARMACEUTICALS USA, INC. V. MONOSOL RX, LLC
`
`

`
`Index of Claims
`
`Application/Control No.
`
`95002170
`
`Examiner
`
`ALAN DIAMOND
`
`Applicant( s )/Patent Under
`Reexamination
`7897080
`
`Art Unit
`
`3991
`
`Rejected
`
`Allowed
`
`--
`
`Cancelled
`
`N
`
`Non-Elected
`
`Restricted
`
`Interference
`
`A
`
`0
`
`Appeal
`
`Objected
`
`D Claims renumbered in the same order as presented by applicant
`
`D CPA
`
`D T.D.
`
`D R.1.47
`
`CLAIM
`Final
`Original
`253
`254
`255
`256
`257
`258
`259
`260
`261
`262
`263
`264
`265
`266
`267
`268
`269
`270
`271
`272
`273
`274
`275
`276
`277
`278
`279
`280
`281
`282
`283
`284
`285
`286
`287
`288
`
`10/08/2012
`./
`
`DATE
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`U.S. Patent and Trademark Office
`
`Part of Paper No.: 20t2t002
`
`Page 2841
`
`TEVA EXHIBIT 1007
`TEVA PHARMACEUTICALS USA, INC. V. MONOSOL RX, LLC
`
`

`
`Index of Claims
`
`Application/Control No.
`
`95002170
`
`Examiner
`
`ALAN DIAMOND
`
`Applicant( s )/Patent Under
`Reexamination
`7897080
`
`Art Unit
`
`3991
`
`Rejected
`
`Cancelled
`
`N
`
`Non-Elected
`
`=
`
`Allowed
`
`Restricted
`
`Interference
`
`A
`
`0
`
`Appeal
`
`Objected
`
`D Claims renumbered in the same order as presented by applicant
`
`D CPA
`
`D T.D.
`
`D R.1.47
`
`DATE
`
`CLAIM
`Final
`Original
`289
`290
`291
`292
`293
`294
`295
`296
`297
`298
`299
`
`10/08/2012
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`./
`
`U.S. Patent and Trademark Office
`
`Part of Paper No.: 20t2t002
`
`Page 2842
`
`TEVA EXHIBIT 1007
`TEVA PHARMACEUTICALS USA, INC. V. MONOSOL RX, LLC
`
`

`
`Transmittal of Communication to
`Third Party Requester
`Inter Partes Reexamination
`
`Control No.
`
`95/002,170
`Examiner
`
`Patent Under Reexamination
`
`7897080
`Art Unit
`
`3991
`-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address. --
`
`Alan Diamond
`
`'I --(THIRD PARTY REQUESTER'S CORRESPONDENCE ADDRESS) ----,1
`
`Danielle L. Herrit
`McCarter & English LLP
`265 Franklin Street
`Boston, MA 02110
`
`Enclosed is a copy of the latest communication from the United States Patent and Trademark Office
`in the above-identified reexamination proceeding. 37 CFR 1.903.
`
`Prior to the filing of a Notice of Appeal, each time the patent owner responds to this communication,
`the third party requester of the inter partes reexamination may once file written comments within a
`period of 30 days from the date of service of the patent owner's response. This 30-day time period is
`statutory (35 U.S. C. 314(b)(2)), and, as such, it cannot be extended. See also 37 CFR 1.947.
`
`If an ex parte reexamination has been merged with the inter partes reexamination, no responsive
`submission by any ex parte third party requester is permitted.
`
`All correspondence relating to this inter partes reexamination proceeding should be directed to the
`Central Reexamination Unit at the mail, FAX, or hand-carry addresses given at the end of the
`communication enclosed with this transmittal.
`
`U.S. Patent and Trademark Office
`PTOL-2070 (Rev. 07·04)
`
`PaperNo.20121002
`
`Page 2843
`
`TEVA EXHIBIT 1007
`TEVA PHARMACEUTICALS USA, INC. V. MONOSOL RX, LLC
`
`

`
`INTER PARTES REEXAMINATION
`COMMUNICATION
`
`Control No.
`
`95/002,170
`Examiner
`
`Alan Diamond
`
`Patent Under Reexamination
`
`7897080
`Art Unit
`
`3991
`
`-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address. --
`
`BELOW/ATTACHED YOU WILL FIND A COMMUNICATION FROM THE UNITED STATES PATENT
`AND TRADEMARK OFFICE OFFICIAL(S) IN CHARGE OF THE PRESENT REEXAMINATION
`PROCEEDING.
`
`All correspondence relating to this inter partes reexamination proceeding should be directed to the
`Central Reexamination Unit at the mail, FAX, or hand-carry addresses given at the end of this
`communication.
`
`U.S. Patent and Trademark Office
`PTOL-2072 (5/04)
`
`PaperNo.20121002
`
`Page 2844
`
`TEVA EXHIBIT 1007
`TEVA PHARMACEUTICALS USA, INC. V. MONOSOL RX, LLC
`
`

`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`REEXAM CONTROL NUMBER
`95/002,170
`
`FILING OR 371 (c) DATE
`09/10/2012
`
`23869
`Hoffmann & Baron LLP
`6900 Jericho Turnpike
`Syosset, NY 11791
`
`Ul\TfED STI\TES DEPA RTME'IT OF COMMERCE
`United States Patent and Trademark Office
`Adill"'· COMMISSIO'JER FOR PATENTS
`PO Box 1450
`Alexandria, Virgmia 22313-1450
`\VVi\V.USpto.gov
`
`PATENT NUMBER
`7897080
`CONFIRMATION NO. 6418
`ASSIGNMENT NOTICE
`
`IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII~I!IJ~~~~~~~~~~~~~~~~~~
`
`Date Mailed: 09/17/2012
`
`NOTICE OF ASSIGNMENT OF INTER PARTES REEXAMINATION REQUEST
`
`The above-identified request for inter partes reexamination has been assigned to Art Unit 3991. All future
`correspondence in this proceeding should be identified by the control number listed above and directed to: Mail
`Stop Inter Partes Reexam, Commissioner for Patents, P.O. Box 1450, Alexandria VA 22313-1450.
`
`A copy of this Notice is being sent to the latest attorney or agent of record in the patent file or, if none is of record,
`to all owners of record. (See 37 CFR 1.33(c).) If the addressee is not, or does not represent, the current owner,
`he or she is required to forward all communications regarding this proceeding to the current owner(s)
`
`(MPEP 2222). An attorney or agent receiving this communication who does not represent the current owner(s)
`may wish to seek to withdraw pursuant to 37 CFR 1.36 in order to avoid receiving future communications. If the
`address of the current owner(s) is unknown, this communication should be returned with the request to withdraw
`pursuant to Section 1.36.
`
`cc: Third Party Requester
`DANIELLE L. HERRITT
`MCCARTER & ENGLISH LLP,
`265 FRANKLIN STREET
`BOSTON, MA 02110
`
`/sdstevenson/
`
`Legal Instruments Examiner
`Central Reexamination Unit 571-272-7705; FAX No. 571-273-9900
`
`page 1 of 1
`
`Page 2845
`
`TEVA EXHIBIT 1007
`TEVA PHARMACEUTICALS USA, INC. V. MONOSOL RX, LLC
`
`

`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`REEXAM CONTROL NUMBER
`95/002,170
`
`FILING OR 371 (c) DATE
`09/10/2012
`
`DANIELLE L. HERRITT
`MCCARTER & ENGLISH LLP,
`265 FRANKLIN STREET
`BOSTON, MA 02110
`
`Ul\TfED STI\TES DEPA RTME'IT OF COMMERCE
`United States Patent and Trademark Office
`Adill"'· COMMISSIO'JER FOR PATENTS
`PO Box 1450
`Alexandria, Virgmia 22313-1450
`\VVi\V.USpto.gov
`
`PATENT NUMBER
`7897080
`CONFIRMATION NO. 6418
`REEXAM ASSIGNMENT NOTICE
`
`IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII~I!IJ~~~~~~~~~~~~~~~~ ~~
`
`Date Mailed: 09/17/2012
`
`NOTICE OF INTER PARTES REEXAMINATION REQUEST FILING DATE
`
`Requester is hereby notified that the filing date of the request for inter partes reexamination is 09/10/2012, the
`date that the filing requirements of 37 CFR § 1.915 were received.
`
`A decision on the request for inter partes reexamination will be mailed within three months from the filing date of
`the request for inter partes reexamination. (See 37 CFR 1.923.)
`
`A copy of this Notice is being sent to the person identified by the requestor as the patent owner. Further patent
`owner correspondence will be with the latest attorney or agent of record in the patent file. (See 37 CFR 1.33.) Any
`paper filed should include a reference to the present request for inter partes reexamination (by Reexamination
`Control Number) and should be addressed to: Mail Stop Inter Partes Reexam, Commissioner for Patents, P.O.
`Box 1450, Alexandria VA 22313-1450.
`
`cc: Patent Owner
`23869
`Hoffmann & Baron LLP
`6900 Jericho Turnpike
`Syosset, NY 11791
`
`/sdstevenson/
`
`Legal Instruments Examiner
`Central Reexamination Unit 571-272-7705; FAX No. 571-273-9900
`
`page 1 of 1
`
`Page 2846
`
`TEVA EXHIBIT 1007
`TEVA PHARMACEUTICALS USA, INC. V. MONOSOL RX, LLC
`
`

`
`REEXAMINATION TITLE REPORT (AKA PATENT ASSIGNMENT ABSTRACT
`OF TITLE)
`
`TYPE OF REEXAMINATION:
`
`EX PARTE
`
`X
`
`INTER PARTES
`
`REEXAM CONTROL NO.: 95/002170
`
`SERIAL NUMBER: 12/614928
`
`FILING DATE: 09/10/12
`
`PATENT NUMBER: 7897080
`
`ISSUE DATE: 03/01/11
`
`FIRST THREE INVENTORS' NAMES: ROBERT K. YANG; RICHARD C. FUISZ; GARY L.
`MYERS
`
`ET. AL?:
`
`X
`
`y
`
`N
`
`CONTINUITY DATA (IF ANY):
`
`_THIS IS (OR) A _CON_ DIV, CIP, A _PROVISIONAL APPLICATION_ OTHER OF
`SERIAL NUMBER , FILED ON. STATUS: PATENTED WITH PATENT NUMBER
`OR_PENDING, OR _ABANDONED (EXPIRED FOR PROVISIONALS).
`
`_ WHICH IS A_ CON,_ DIV, _CIP, A_PROVISIONAL APPLICATION,_ OTHER, OF
`SERIAL NUMBER FILED ON. STATUS: PATENTED, WITH PATENT NUMBER. AND SERIAL
`NUMBER FILED PENDING, OR ABANDONED.
`
`_WHICH IS A_ CON, _DIV, _CIP, A _PROVISIONAL APPLICATION,_ OTHER OF SERIAL
`NUMBER FILED ON . STATUS: PATENTED WITH PATENT NUMBER OR PENDING,
`OR ABANDONED.
`-
`
`WHICH IS A CON, DIV, CIPA PROVISIONAL APPLICATION,
`OTHER OF SERIAL
`NUMBER FILED-ON. STATUS: PATENTED WITH PATENT NUMBER: OR PENDING, OR
`ABANDONED.
`-
`
`_WHICH IS A CON, DIV, _CIP A PROVISIONAL APPLICATION, _OTHER OF SERIAL
`NUMBER FILED ON. STATUS: PATENTED WITH PATENT NUMBER: OR_PENDING, OR
`ABANDONED.
`
`_WHICH IS A CIP OF SERIAL NUMBER FILED ON. STATUS: PATENTED, WITH PATENT
`NUMBER.
`
`ETAL
`
`ASSIGNMENT RECORD DATA
`
`THE ASSIGNMENT RECORDS REVEAL THAT THE TITLE REPORT APPEARS TO BE
`VESTED IN:
`
`Page 2847
`
`TEVA EXHIBIT 1007
`TEVA PHARMACEUTICALS USA, INC. V. MONOSOL RX, LLC
`
`

`
`xxxiNVENTOR(S) ROBERT K. YANG; RICHARD C. FUISZ; GARY L. MYERS; JOSEPH M.
`FUISZ
`
`_AS ENDORSED:
`(
`_AS THE RECORD STANDS, THE PATENT WHEN GRANTED WILL ISSUE IN THE NAME
`OF THE INVENTOR(S)
`
`_LEGAL REPRESENTATIVE:
`
`_SECURITY ASSIGNMENT/LICENSEE(PLEASE NOTE THAT THE OWNERSHIP OF THE
`PATENT IS STILL REFLECTED IN THE ASSIGNOR. THE ASSIGN££ IN THIS CASE CANNOT
`OWN THE PATENT. (SEE ACCOMPANYING PAGES, IF ANY.)
`
`_WHEN THE ASSIGNMENT IS RECORDED, THE PATENT SHOULD BELONG TO:
`
`_OTHER: REEL NO: FRAME NO.: DATE RECORDED: II COMPANY NAME:
`CITY AND STATE OR COUNTRY: .
`
`_NOTES/COMMENTS: Please see section 306 of the Manual of Patent Examining Procedure
`regarding the Assignment of a Division, Continuation, Substitute, and
`Continuation-in-Part in Relation to Parent Application.
`
`EXAMINED UP TO AND INCLUDING THIS CERTIFICATE DATED AND SIGNED: 09/14/12
`
`LEGAL INSTRUMENTS EXMR., OFFICE OF PATENT LEGAL ADMIN., CENTRAL
`REEXAMINATION UNIT
`
`TO ANY PRINTERS: THE REEXAMINATION TITLE REPORT DOES NOT HA V£ TO HA V£
`THE STREET ADDRESS OF THE OWNER(S). IF THERE IS ANY INQUIRY, PLEASE NOTIFY
`THE PERSON ABOVE.
`
`Page 2848
`
`TEVA EXHIBIT 1007
`TEVA PHARMACEUTICALS USA, INC. V. MONOSOL RX, LLC
`
`

`
`Reexam Control No 95/002,170
`
`Litigation Search Report CRU 3999
`::~i:~~~ ·
`"·
`From: Tredelle Jackson
`Location: CRU 3999
`MOE 5030
`Phone: (571) 272-2783
`Tredelle.Jackson@us pto.gov
`
`TO: Examiner
`Location: CRU
`Art Unit: 3991
`Date: 09/13/12
`Case Serial Number: 95/002,170
`
`Litigation Search for U.S. Patent Number 7,897,080.
`
`Sources:
`
`1) I performed a KeyCite Search in Westlaw, which retrieves all history on the patent including any
`·
`litigation.
`
`2) I performed a search on the patent in Lexis CourtLink for any open dockets or closed cases.
`
`3) I performed a search in Lexis in the Federal Courts and Administrative Materials databases for any cases
`found.
`
`4) I performed a search in Lexis in the IP Journal and Periodicals database for any articles on the patent.
`
`5) I performed a search in Lexis in the news databases for any articles about the patent or any articles about
`·
`litigation on this patent.
`
`Page 2849
`
`TEVA EXHIBIT 1007
`TEVA PHARMACEUTICALS USA, INC. V. MONOSOL RX, LLC
`
`

`
`Date of Printing: Sep 13,2012
`
`KEY CITE
`
`C US PAT 7897080 POLYETHYLENE-OXIDE BASED FILMS AND DRUG DELIVERY SYSTEMS
`MADE THEREFROM, Assignee: MonoSol Rx, LLC (Mar 01, 2011)
`History
`Direct History
`
`=>
`
`1 POLYETHYLENE-OXIDE BASED FILMS AND DRUG DELIVERY SYSTEMS MADE
`THEREFROM, US PAT 7897080,2011 WL 693980 (U.S. PTO Utility Mar 01, 2011)
`
`Patent Family
`2 INGESTIBLE WATER-SOLUBLE DELIVERY SYSTEM IN THE FORM OF A FILM COM(cid:173)
`POSITION USEFUL FOR THE PREPARATION OF A DRIED FILM COMPRISES GLUCAN
`AND A WATER-SOLUBLE POLYMER, Derwent World Patents Legal 2003-430230+
`
`Prior Art (Coverage Begins 1976)
`3 BIOADHESIVE HOT-MELT EXTRUDED FILM FOR TOPICAL AND MUCOSAL ADHE-
`SION APPLICATIONS AND DRUG DELIVERY AND PROCESS FOR PREPARATION
`THEREOF, US PAT 6375963 (U.S. PTO Utility 2002)
`4 BIOERODABLE FILM FOR DELIVERY OF PHARMACEUTICAL COMPOUNDS TO MU-
`COSAL SURF ACES, US PAT 5800832Assignee: Virotex Corporation, (U.S. PTO Utility 1998)
`5 DERMAL BANDAGE AND DERMAL PREPARATION, US PAT4880416Assignee: Nitto
`Electric Industrial Co., Ltd., (U.S. PTO Utility 1989)
`6 DRUG LOADED POLYMERIC MATERIAL AND METHOD OF MANUFACTURE, US PAT
`5605696Assignee: Advanced Cardiovascular Systems, Inc., (U.S. PTO Utility 1997)
`7 DRYING PROCESS, US PAT 4872270Assignee: Eastman Kodak Company, (U.S. PTO Utility
`1989)
`8 EXTRUDABLE COMPOSITIONS FOR TOPICAL OR TRANSDERMAL DRUG DELIVERY,
`US PAT 60721 OOAssignee: Johnson & Johnson Consumer Products, (U.S. PTO Utility
`2000)
`9 MEDICAMENT CARRIERS IN THE FORM OF FILM HAVING ACTIVE SUBSTANCE IN-
`CORPORATED THEREIN, US PAT 4136145Assignee: Schering Aktiengesellschaft, (U.S. PTO
`Utility I 979)
`10 METHOD AND APPARATUS FOR DRYING FRUIT PULP AND THE LIKE, US PAT
`4631837 (U.S. PTO Utility 1986)
`II METHOD AND SYSTEM FOR PRODUCING SEALED PACKAGES OF A FILM WHICH IS
`DISSOLVED IN A BODY FLUID, US PAT 5806284Assignee: Apothecus Pharmaceutical
`Corp., (U.S. PTO Utility 1998)
`
`C
`
`C
`
`C
`
`C
`
`C
`
`C
`
`C
`
`C
`
`C
`
`© 2012 Thomson Reuters. All rights reserved.
`
`Page 2850
`
`TEVA EXHIBIT 1007
`TEVA PHARMACEUTICALS USA, INC. V. MONOSOL RX, LLC
`
`

`
`C
`
`C
`
`C
`
`C
`
`C
`
`C
`
`C
`
`C
`
`C
`
`C
`
`C
`
`C
`
`C
`
`C
`
`C
`
`C
`
`12 METHOD FOR PRODUCING FILM-TYPE DOSAGE, US PAT 6800329Assignee: LTS
`Lohmann Therapie-Systeme AG, (U.S. PTO Utility 2004)
`13 METHOD OF FORMING AN EDIBLE MEDICINAL WAFER STRIP PACKAGE, US PAT
`3007848 (U.S. PTO Utility 1961)
`14 METHODS FOR CONVERSION OF PROTEIN ISOFORMS, US PAT 6281337Assignee: Scher-
`ing Corporation, (U.S. PTO Utility 2001)
`15 METHODS FOR MANUFACTURING ARTICLES FROM SHEETS OF UNHARDENED HY-
`DRAULICALLY SETT ABLE COMPOSITIONS, US PAT 5766525Assignee: E. Khashoggi In(cid:173)
`dustries, (U.S. PTO Utility 1998)
`16 PHARMACEUTICAL CARRIER DEVICE SUITABLE FOR DELIVERY OF PHARMACEUT-
`ICAL COMPOUNDS TO MUCOSAL SURFACES, US PAT 7579019Assignee: Arius Two, Inc.,
`(U.S. PTO Utility 2009)
`17 POLYETHYLENE OXIDE-BASED FILMS AND DRUG DELIVERY SYSTEMS MADE
`THEREFROM, US PAT 7666337Assignee: MonoSol Rx, LLC, (U.S. PTO Utility 2010)
`18 POLYETHYLENE OXIDE-BASED FILMS AND DRUG DELIVERY SYSTEMS MADE
`THEREFROM, US PAT APP 20050037055Assignee: MonoSoiRx LLC., (U.S. PTO Application
`2005)
`19 PROCESS FOR MAKING AN INGESTIBLE FILM, US PAT 7357891Assignee: MonoSol Rx,
`LLC, (U.S. PTO Utility 2008)
`20 PROCESS FOR MANUFACTURING THIN FILM STRIPS, US PAT 6824829Assignee: Acupac
`Packaging, Inc., (U.S. PTO Utility 2004)
`21 PROCESS FOR PRODUCING AN ADMINISTRATION OR DOSAGE FORM FOR DRUGS,
`REAGENTS OR OTHER ACTIVE INGREDIENTS, US PAT 4849246 (U.S. PTO Utility 1989)
`22 RAPIDLY DISINTEGRATING SHEET-LIKE PRESENTATIONS OF MULTIPLE DOSAGE
`UNITS, US PAT 5629003Assignee: LTS Lohmann Therapie-Systeme GmbH &, (U.S. PTO
`Utility 1997)
`23 TEXTURED-FOAM COATED URETHANE WALL AND CEILING COVERING AND METH-
`OD OF MAKING THE SAME, US PAT 4049848Assignee: United Foam Corporation, (U.S.
`PTO Utility 1977)
`24 THIN FILM WITH NON-SELF-AGGREGATING UNIFORM HETEROGENEITY AND DRUG
`DELIVERY SYSTEMS MADE THEREFROM, US PAT APP 20040258896Assignee: Mono(cid:173)
`SolRx LLC., (U.S. PTO Application 2004)
`25 THIN FILM WITH NON-SELF-AGGREGATING UNIFORM HETEROGENEITY AND DRUG
`DELIVERY SYSTEMS MADE THEREFROM, US PAT APP 20030107149Assignee: INTER(cid:173)
`NATIONAL FLUIDICS., (U.S. PTO Application 2003)
`26 VETERINARY DELIVERY SYSTEMS AND METHODS OF DELIVERING EFFECTIVE
`AGENTS TO ANIMALS, US PAT 7005142 (U.S. PTO Utility 2006)
`27 WATER SOLUBLE FILM FOR ORAL ADMINISTRATION WITH INSTANT WETTABIL-
`ITY, US PAT 5948430Assignee: L TS Lohmann Therapie-Systeme GmbH, (U.S. PTO Utility
`1999)
`
`© 2012 Thomson Reuters. All rights reserved.
`
`Page 2851
`
`TEVA EXHIBIT 1007
`TEVA PHARMACEUTICALS USA, INC. V. MONOSOL RX, LLC
`
`

`
`LexisNexis· CourtLink·
`My Briefcase 1 Order Runner Documents 1 Available Courts I Total Utigator I Lexis.com 1 ~ 1 Learning Center
`Welcome, Tredelle Jackson
`
`Single Search - with Terms and Connectors
`IE.~terkeyword_s - Search multiple dockets & documents
`
`-.Dockets & Documents
`
`':Strategic Profiles : _.: My Account \
`
`Search > Patent Search > Searching
`
`Patent Search 7897080 9/13/2012
`
`No cases found.
`*;w+:'fflt+dN
`
`{Charges for search still apply}
`
`A®lexisNexise.> ' About LexisNexis I Terms & Conditions I Pricing I Privacy I Customer Support- 1-888-
`W
`311-1966
`Copyright© 2012 LexisNexis®. All rights reserved.
`
`Page 2852
`
`TEVA EXHIBIT 1007
`TEVA PHARMACEUTICALS USA, INC. V. MONOSOL RX, LLC
`
`

`
`1. US Fed News, March 5, 2011 Saturday 12:06 PM EST,, 245 words, US Patent Issued to
`MonoSol Rx on March 1 for "Polyethylene-Oxide Based Films and Drug Delivery
`Systems Made Therefrom" (District Of Columbia, New York, Virginia, Tennessee
`Inventors), ALEXANDRIA, Va .
`
`... r=1&f=G&I=50&co1=AND&d=PTXT&s1=7897080&0S=7897080&RS=7897080
`For any query with respect to this article or any other content requirement, please ...
`2. Tendersinfo News, July 28, 2011 Thursday 6:30AM EST,, 128 words, ITALY : Edil CO.
`SRL wins contract of 5 080 915 Euros
`
`... di Bari - ripartizione contratti ed appalti, Italy has issued the contract of 5 080 915
`Euros to Edil CO. SRL, Italy for execution of restoration work. This ...
`... per open procedure method. Initial estimated total value of the contract was 8 897
`000 EUR and the final contract award value was 5 080 915 EUR. Total 11 number of
`offers received for this tender. GPA has ...
`3. Tendersinfo, July 28, 2011 Thursday, 107 words, ITALY : Edil CO. SRL wins contract of
`5 080 915 Euros, Tejas98
`
`... di Bari - ripartizione contratti ed appalti, Italy has issued the contract of 5 080 915
`...
`Euros to Edil CO. SRL, Italy for execution of restoration work. Th'is
`... per open procedure method. Initial estimated total value of the contract was 8 897
`000 EUR and the final contract award value was 5 080 915 EUR. Total 11 number of
`offers received for this tender. GPA has ...
`4. Financial Law Reporter, April 5, 2011, 253317030, 897 words, Cross Refrence Citation
`Name : 1981 SCMR 198 SUPREME-COURT .
`
`. . . Versus MUNIR HUSSAIN AND 2 OTHERS-Respondents Civil Petition No. 285 of 080, .
`decided on 8th April, 1980. (On appeal from the judgment and order dated ...
`April 7, 2011
`5. News Bites US Markets, May 7, 2011 Saturday, 418 words, Weekly: Sinovac Biotech
`price 7.1% below volume weighted price
`
`... turnover rate in the 12 months to date was 155.3% (or a turnover period of 7
`months). Rises to Falls: In the last six months the number of falls outnumbered ...
`... value of US$1,000 invested thirteen weeks ago is US$897 [vs US$1,022 for the
`NASDAQ-100 index] for a ...
`... SVA $1US,OOO $897 $1US,619
`Total NASDAQ Market $1US,017 $1US,080 $1US,675 ...
`May 7, 2011
`6. Plus NEWS, March 5, 2011, 250627097, 79 words, World Stock Reports: Casablanca
`Stock Exchange Ltd Best 10 capitalisation: 05-03-2011.
`
`ITISSALAT AL-MAGHRIB 138 897 063 720,00 ...
`CGI 30 097 080 000,00 ...
`7. News Bites US Markets, November 10, 2010 Wednesday, 1052 words, American
`Independence Corp. closes at 4.0% above VWP but at 26.0% discount to 52-week high
`
`... Volatility: the stock traded between an intraday low of US$4.73 and seven-day high
`of US$4.85, suggesting a trading opportunity between ...
`.. . strength of 40 which means it has underperformed 60.0% of the market. Volume
`and turnover period: there were 897 shares worth US$4,350 traded. The volume was
`
`Page 2853
`
`TEVA EXHIBIT 1007
`TEVA PHARMACEUTICALS USA, INC. V. MONOSOL RX, LLC
`
`

`
`0.4 times average ...
`... in the 12 months to date was 7.3% (or a turnover period of 13 years 7 months).%
`Discount to high: the last price is at a discount of 26.0% to the
`... Insurance $1US,080 $23US,097
`NASDAQ-100 $1US,080 $1US,238 ...
`
`8. News Bites US Markets, November 5, 2010 Friday, 931 words, Cardium Therapeutics
`gains 4.3% on low volume
`
`... value of US$1,000 invested a month ago is US$897 [vs US$1,048 for the NYSE U.S.
`100 index], for ...
`... CXM $897 $731
`Health Care $1US,039 $1US,080 ...
`November 7, 2010
`
`9. News Bites US Markets, May 7, 2011 Saturday, 618 words, Weekly: Cornerstone
`Financial slides 5.3% on thin volume
`
`... value of US$1,000 invested thirteen weeks ago is US$897 [vs US$1,019 for the
`NASDAQ-100 index] for a .. .
`... CFIC $897 $1US,080 .. .
`May 7, 2011
`
`10. News Bites US Markets, November 5, 2010 Friday, 1259 words, Overland Storage
`closes at 5.4% below VWP but at 6.6% premium to 52-week low
`
`... value of US$1,000 invested a month ago is US$897 [vs US$1,081 for the NASDAQ-
`100 index], for a ...
`. . . OVRL $897 $549
`Computers & Electronics $1US,080 $1US,256 ...
`November 7, 2010
`
`Combined Source Set 41Il - News, Most Recent Two Years (English, Full Text)
`Source:
`7897080 or 7,897,080 (Suggest Terms for My Search 1 Feedback on Your Search)
`Terms:
`.
`Cite
`View:
`Date/Time: Thursday, September 13, 2012- 3:56PM EDT
`
`In
`
`1 Contact Us
`I Terms & Conditions
`1 Privacy Policy
`About LexisNexis
`Copyright© 2012 LexisNexis, a division of Reed Elsevier Inc. All rights reserved.
`
`Page 2854
`
`TEVA EXHIBIT 1007
`TEVA PHARMACEUTICALS USA, INC. V. MONOSOL RX, LLC
`
`

`
`614928 (12) 7897080 March 1, 2011
`
`UNITED STATES PATENT AND TRADEMARK OFFICE GRANTED PATENT
`
`7897080
`
`Get Drawing Sheet 1 of 34
`Access PDF of Official Patent *
`Order Patent File History I Wrapper from REEDFAX®
`Link to Claims Section
`
`March 1, 2011
`
`Polyethylene-oxide based films and drug delivery systems made therefrom
`
`INVENTOR: Yang, Robert K. - Flushing, New York, United States of America (US), United
`States of America () ; Fuisz, Richard C. - Mclean, Virginia, United States of America (US),
`United' States of America () ; Myers, Gary L. - Kingsport, Tennessee, United States of America
`(US), United States of America () ; Fuisz, Joseph M. - Washington, District of Columbia, United
`States of America (US), United States of America ()
`
`APPL-NO: 614928 (12)
`
`FILED-DATE: November9, 2009
`
`GRANTED-DATE: March 1, 2011
`
`CORE TERMS: film, composition, drying, polymer, dried, desirably, particle, coating, flavor,
`viscosity, ingredient, mixing, uniformity, dosage, heat, drop, simethicone, moisture, cellulose,
`minutes, mixture, acid, calcium, solvent, oven, film-forming, carbonate, soluble, zone, vacuum
`
`ENGLISH-ABST:
`
`The invention relates to the film products and methods of their preparation that demonstrate a
`non-self-aggregating uniform heterogeneity. Desirably, the films disintegrate in water and may
`be formed by a controlled drying process, or other process that maintains the required
`uniformity of the film. The films contain a polymer component, which includes polyethylene
`oxide optionally blended with hydrophilic cellulosic polymers. Desirably, the films also contain a
`pharmaceutical and/or cosmetic active agent with no more than a 10% variance of the active
`agent pharmaceutical and/or cosmetic active agent per unit area of the film.
`
`Source:
`Terms:
`View:
`Date/Time:
`
`Command Searching > Utility, Design and Plant Patents II)
`patno=7897080 (Suggest Terms for My Search)
`SuperKWIC
`Thursday, September 13, 2012- 3:58PM EDT
`
`In
`
`About LexisNexis 1 Privacy Policy 1 Terms & Conditions 1 Contact Us
`Copyright© 2012 LexisNexis, a division of Reed Elsevier Inc. All rights reserved.
`
`Page 2855
`
`TEVA EXHIBIT 1007
`TEVA PHARMACEUTICALS USA, INC. V. MONOSOL RX, LLC
`
`

`
`PTO/SB/58 (02-12)
`Approved for use through 02/28/2013. OMB 0651-0033
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.
`(Also referred to as FORM PT0-1465)
`REQUEST FOR INTER PARTES REEXAMINATION TRANSMITTAL FORM
`
`Address to:
`Mail Stop Inter Partes Reexam
`Commissioner for Patents
`P.O. Box 1450
`Alexandria, VA 22313-1450
`
`Attorney Docket No.: 117744-00023
`
`Date: September 10. 2012
`
`1.1:8:1 This is a request for inter partes reexamination pursuant to 37 CFR 1.913 of patent number 7,897,080 issued
`03/01/2011. The request is made by a third party requester, identified herein below.
`
`2.1:8:1 a. The name and address of the person requesting reexamination is:
`
`Danielle L. Herritt
`
`McCarter & English LLP, 265 Franklin Street
`
`Boston, MA 02110
`
`BioDelivery Sciences International, 801 Corporate Center
`b. The real party in interest (37 CFR 1.915(b)(8)) is: Drive, Suite 210, Raleigh, NC 27607
`3. D a. A check in the amount of$ ___ is enclosed to cover the reexamination fee, 37 CFR 1.20(c)(2);
`I:8J b. The Director is hereby authorized to charge the fee as set f